Equity shareholders of Alkem Laboratories approved the proposed scheme of amalgamation with Adroit Biomed Limited (ABL) on August 17, 2026. The special resolution received 99.9999% support in value terms, reflecting broad consensus across promoter and public shareholder categories. The meeting was held via video conferencing and other audio-visual means, as directed by the National Company Law Tribunal (NCLT), Mumbai Bench.

The NCLT had previously issued an order on June 10, 2026, sanctioning the convening of the meeting for the scheme under Sections 230 to 232 of the Companies Act, 2013. Mr. Harihar Prakash Chaturvedi, former Additional Secretary at the Ministry of Law and Justice and Judicial Member of the NCLT Mumbai, chaired the proceedings. The requisite quorum was present when the meeting commenced at 11:15 am.

Voting Breakdown

Shareholders were provided remote e-voting facilities from August 12 to August 16, 2026, followed by e-voting during the virtual meeting. A total of 879 shareholders participated in the voting process, representing 9,99,85,296 votes polled out of 1,19,56,50,000 outstanding shares. This translates to a participation rate of approximately 83.62%.

The promoter group, holding 5,94,24,889 shares, voted unanimously in favour. Similarly, public institutions holding 3,96,07,384 shares cast all their polled votes (3,71,30,858) in support of the amalgamation. Only 84 votes were cast against the resolution, all from the public non-institutional category.

What the Numbers Show

The voting data reveals near-unanimous institutional backing for the transaction. With promoters and public institutions accounting for 95.06% and 93.74% of their respective shareholdings in the vote pool respectively, and both categories voting 100% in favour, the opposition was negligible. The single dissenting signal came exclusively from retail or small non-institutional investors, who cast just 84 votes against the deal despite a high participation rate of 30.98% within that segment.

Procedural Compliance

Ritul Parmar, a practicing Company Secretary, served as the scrutinizer for the e-voting process. The scrutinizer’s report confirmed compliance with the Companies Act, 2013, and SEBI Listing Regulations. The notice for the meeting was published in Business Standard and Navshakti on July 16, 2026. The resolution authorizes the Board of Directors to execute all necessary acts, deeds, and agreements to give effect to the scheme, including modifications required by regulatory authorities.

Alkem Laboratories Limited intimated that its trading window for directors and specified officials will open on August 17, 2026. The move follows the company's communication of financial results for the quarter ended June 30, 2026, to the stock exchanges.

The trading window had remained closed since June 29, 2026. This closure was mandated for the purpose of finalizing financial results for the first quarter of FY27. The window was scheduled to reopen after the expiry of 48 hours from the date the results were communicated to the exchanges.

Manish Narang, President - Legal, Company Secretary & Compliance Officer, signed the intimation on August 14, 2026. The company notified both the BSE Limited and the National Stock Exchange of India Limited regarding the schedule change.

Regulatory Compliance

The intimation aligns with SEBI regulations governing insider trading and the conduct of directors and designated officers. Companies are required to close trading windows during sensitive periods leading up to the announcement of financial results to prevent potential misuse of unpublished price-sensitive information.

The closure period began on June 29, 2026, as per earlier communication dated June 24, 2026. With the results now public, the restriction is lifted effective August 17, 2026.